Company: HROW
Filing Date: 2025-11-10
Form Type: 10-Q
Source: 0001493152-25-021562
Chunk: 60

Company: HARROW, INC.
Filing Date: 2025-11-10
Form: 10-Q
Item: Item 1
Chunk 60
---
 Notes were listed on The Nasdaq Stock Market under the symbols “HROWL”
and “HROWM”, respectively. The 2026 Notes were delisted on October 10, 2025 and the 2027 Notes were delisted on October 8,
2025.

BYOOVIZ®
and OPUVIZTM – Commercialization Agreement

In
July 2025, we entered into a development and commercialization agreement (the “Samsung Agreement”) with Samsung Bioepis Co.,
Ltd. (“Samsung”). Under the terms of the Samsung Agreement, following completion of the transition of commercial rights from
Biogen, Inc. back to Samsung, Samsung will develop, manufacture, and supply BYOOVIZ (ranibizumab-nuna) and OPUVIZ (aflibercept-yszy)
(individually, a “Product” and together, the “Products”) for Harrow to commercialize in the U.S. market (the
“Rights”). In consideration of such Rights, we will make a one-time upfront payment to Samsung, and Samsung will be eligible
to receive additional one-time payments based on the achievement of net sales-based milestones of the Products. In addition to other
mutually agreed terms, we shall pay to Samsung a share of net sales from the Products generated in the U.S. market.

33

Acquisition
of Commercial Rights to BYQLOVITM

In
June 2025, we announced a licensing agreement whereby we acquired the exclusive U.S. commercial rights to BYQLOVI (clobetasol propionate
ophthalmic suspension) 0.05% from Taiwan-based Formosa Pharmaceuticals. BYQLOVI was recently approved by the FDA for the treatment of
post-operative inflammation and pain following ocular surgery and is the first new ophthalmic steroid in its class in over 15 years.
Harrow expects BYQLOVI to be available in the fourth quarter of 2025.

VEVYE® Access for All

In
March 2025, we announced a patient access program called VEVYE Access for All. The program is designed to increase patient access to
VEVYE at an out-of-pocket cost of $59 or below and, in many cases, reduce the need for prior authorizations, step edits, and other treatment
obstacles facing dry eye patients and their prescribers.

Project
Beagle

During
the first quarter of 2025 we initiated a 360-degree